Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

CLEAR report 1: a scoping review and meta-analysis for definitions, imaging metrics, and functional correlates of photoreceptor integrity in AMD.

Created on 29 Jul 2026

Authors

Kimberly L Spooner, Anjali Gaston, Anushka Irodi, Alicia Lim, Omer Trivizki, Livia Faes, Sobha Sivaprasad, Dun Jack Fu

Published in

Frontiers in medicine. Volume 16. Pages 1578813. Epub Jul 06, 2026.

Abstract

Advanced age-related macular degeneration (AMD) is a leading cause of irreversible vision loss worldwide, with photoreceptor degeneration representing the final common pathway of functional impairment. Optical coherence tomography (OCT) enables noninvasive, layer-resolved quantification of photoreceptor integrity using biomarkers of the ellipsoid zone (EZ), the outer nuclear layer (ONL), and the external limiting membrane (ELM). However, substantial heterogeneity in definitions, measurement protocols, and reporting practices limits cross-study comparability and the adoption of clinical trials. This scoping review with nested meta-analyses maps how axial photoreceptor biomarkers are operationalized, segmented, validated, and related to functional and multimodal endpoints in AMD.
MEDLINE, Embase, and Scopus were searched from January 2015 to December 2025 following PRISMA-ScR guidelines. Eligible studies reported OCT-based photoreceptor biomarkers in AMD populations. Data extraction captured boundary definitions, imaging platforms, segmentation approaches, analytic domains, ROI strategies, phenotypic context, reliability statistics, structure-function correlations, and OCT-FAF agreement.
Ninety-four studies met inclusion criteria, spanning spectral-domain and swept-source OCT platforms and diverse AMD phenotypes. Marked variability was observed in boundary definitions (e.g., EZ-RPE vs. EZ-Bruch's membrane), measurement strategies (thickness, area, volume, reflectivity), and spatial sampling (central 1 mm, ETDRS subfields, lesion-centric masks). When segmentation boundaries and analytic conventions were explicitly defined and consistently applied, reliability for EZ and ONL metrics was high (ICC > 0.90), with automated and deep-learning methods performing comparably to expert manual grading. Structure-function analyses demonstrated moderate-to-strong correlations between photoreceptor loss and microperimetry sensitivity (r = 0.50-0.80) and best-corrected visual acuity (r = 0.40-0.70), particularly in advanced disease stages. OCT-FAF agreement for geographic atrophy detection was similarly high (κ > 0.80), although early atrophic features showed greater definitional variability. Phenotypic stratification and topographic reporting were inconsistently documented.
OCT-derived photoreceptor biomarkers show high analytical reliability and clinically meaningful structure-function associations when segmentation boundaries, analytic domains, and reporting conventions are clearly specified. However, the review identifies substantial construct heterogeneity that complicates cross-study comparability and endpoint interpretation. Adoption of consensus boundary definitions, minimum reporting standards, and harmonized validation frameworks is necessary to ensure reproducibility, facilitate regulatory evaluation, and enable integration of photoreceptor metrics into AMD prevention and early-intervention trials. These findings provide the conceptual foundation for the CLEAR initiative (Consensus Layer Evaluation for AI Algorithm Reporting).

PMID:
42518983
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement